{
    "case_number": "CAC-UDRP-101291",
    "time_of_filling": "2016-09-06 09:42:05",
    "domain_names": [
        "lexapro.website",
        "lexapro.press",
        "lexapro.host",
        "lexapro.online",
        "lexapro.tech",
        "lexapro.club"
    ],
    "case_administrator": "Aneta Jelenová (Case admin)",
    "complainant": [
        "H. Lundbeck A\/S"
    ],
    "complainant_representative": "Wallberg IP Advice",
    "respondent": [
        "Albert Sadykov"
    ],
    "respondent_representative": null,
    "factual_background": "FACTS ASSERTED BY THE COMPLAINANT AND NOT CONTESTED BY THE RESPONDENT:\r\n\r\nThe Complainant H. Lundbeck A\/S was founded in 1915 and is now an international pharmaceutical company engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. \r\n\r\nLundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2015, the company's revenue was USD 2.2 billion. Today Lundbeck employs approximately 5.500 people worldwide. \r\n\r\nLundbeck markets a number of different pharmaceuticals for the treatment of brain disorders. The most recently launched compounds include: Cipralex\/Lexapro® (depression), Ebixa® (Alzheimer’s disease), Azilect® (Parkinson’s disease), Xenazine® (chorea associated with Huntington's disease), Sabril® (epilepsy), Sycrest® (bipolar disorder) and Onfi® (Lennox-Gastaut syndrome).\r\n\r\nThe trademark Lexapro® is registered in more than 100 countries around the world.\r\n\r\nWhereas the disputed domain names were, in accordance with the Complaint, not active at the time of the filing of the Complaint, they were at the time of the decision. \r\n\r\nAll the contested domain names \r\n\r\nlexapro.website\r\nlexapro.press\r\nlexapro.host\r\nlexapro.online\r\nlexapro.tech\r\nlexapro.club\r\n\r\nwere active at that time and showed a table of online pharmacies where Lexapro products including Generic Lexapro products are advertised.\r\n",
    "other_legal_proceedings": "The panel is not aware of any other pending proceedings.",
    "no_response_filed": "NO ADMINISTRATIVELY COMPLIANT RESPONSE HAS BEEN FILED.",
    "rights": "The Complainant has, to the satisfaction of the Panel, shown the Domain Names are identical or confusingly similar to a trademark or service mark in which the complainant has rights (within the meaning of paragraph 4(a)(i)of the Policy).",
    "no_rights_or_legitimate_interests": "The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the Domain Names (within the meaning of paragraph 4(a)(ii)of the Policy).",
    "bad_faith": "The Complainant has, to the satisfaction of the Panel, shown the Domain Names have been registered and are being used in bad faith (within the meaning of paragraph 4(a)(iii)of the Policy).",
    "procedural_factors": "The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.",
    "decision": "Accepted",
    "panelists": [
        "Dietrich Beier"
    ],
    "date_of_panel_decision": "2016-10-20 00:00:00",
    "informal_english_translation": "The Complainant enjoys protection for his trademark Lexapro around the world, inter alia by the EUTM Lexapro 002041259, registered on February 23, 2004 in class 5.",
    "decision_domains": {
        "LEXAPRO.WEBSITE": "TRANSFERRED",
        "LEXAPRO.PRESS": "TRANSFERRED",
        "LEXAPRO.HOST": "TRANSFERRED",
        "LEXAPRO.ONLINE": "TRANSFERRED",
        "LEXAPRO.TECH": "TRANSFERRED",
        "LEXAPRO.CLUB": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}